Abstract 10P
Background
There remains uncertainty regarding prognosis and treatment effect in small, node negative breast cancer. We described overall prognosis of small (<1cm), node (-), HER2 (+) breast cancer after curative surgery, and effect of adjuvant treatment. There remains uncertainty regarding prognosis and treatment effect in small, node negative breast cancer. We described overall prognosis of small (<1cm), node (-), HER2 (+) breast cancer after curative surgery, and effect of adjuvant treatment.
Methods
We identified patients who fulfilled inclusion criteria (curative surgery, <1cm, N0, and HER2(+) breast cancer) by medical chart review. We collected data of baseline characteristics, receptor status, surgical method, histologic type, histologic and nuclear grade, adjuvant treatment (chemotherapy, radiotherapy, endocrine therapy, and trastuzumab. We compared baseline characteristics between patients with or without adjuvant treatment (Chi-square), and the prognosis between them (Kaplan meier curve and log-rank test). SPSS version 18.0 was used for statistical analysis.
Results
A total of 429 patients (pT1a=205, pT1b=222) were identified. In patients with pT1a, only 1 patient experienced systemic recurrence and death. No difference was observed in DFS and OS between patients with adjuvant chemotherapy and/or adjuvant trastuzumab. In pT1b, HR(-) patients (N = 52), longer DFS was observed in patients who received adjuvant chemotherapy (p = 0.013). There was no difference in DFS according to trastuzumab treatment (p = 0.441). No difference was found according to adjuvant treatment in overall or HR(+) pT1b patients.
Conclusions
In conclusion, our result showed overall prognosis of small(<1cm), node (-), and HER2+ breast cancer and patients with pT1b and HR(-) patients can benefit from adjuvant chemotherapy. Subsequent study with large sample size is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract